Physician profile
Alka Kaushik
NPI 1275586679
$1,585.40
in general payments reported to CMS, 2019-2025
29 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $258 · 2020: $158 · 2021: $707 · 2022: $462.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.62 | 2021-2022 | |
| Amgen INC. | $237.50 | 2019-2022 | |
| Amarin Pharma, INC. | $106.09 | 2020-2021 | |
| Janssen Pharmaceuticals, INC | $105.33 | 2020-2021 | |
| Lilly USA, LLC | $94.14 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $83.73 | 2019-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $54.64 | 2021-2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $47.10 | 2021-2022 | |
| Tosoh Bioscience, INC. | $47.00 | 2019 | |
| Daiichi Sankyo INC. | $44.44 | 2019-2021 | |
| Boston Scientific Corporation | $40.61 | 2021-2022 | |
| Novo Nordisk INC | $40.23 | 2020-2022 | |
| Corcept Therapeutics | $33.67 | 2019 | |
| Orexo US, INC. | $27.99 | 2019-2022 | |
| Abbott Laboratories | $24.76 | 2021-2022 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $22.29 | 2021 | |
| Biohaven Pharmaceuticals, INC. | $22.07 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $21.94 | 2022 | |
| Idorsia Pharmaceuticals US INC | $20.36 | 2022 | |
| Amneal Pharmaceuticals LLC | $17.43 | 2019 | |
| Dexcom, INC. | $16.61 | 2021 | |
| Radius Health, INC. | $15.08 | 2019 | |
| Glaxosmithkline, LLC. | $14.76 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $14.71 | 2022 | |
| Ibsa Pharma INC. | $14.30 | 2019 | |
| Ironwood Pharmaceuticals, INC | $13.59 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $13.07 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $12.41 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $11.93 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alka Kaushik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.